Researchers from the Institute of Glycomics have been awarded more than $1,100,000 million in National Health and Medical Research Council (NHMRC) grant funding to develop new antibiotics for the treatment of multidrug resistant gonorrhea infections.
This funding enables the team to delve further into the chemistry and potential application of new “zinc-binder” drugs under development to target a range of significant drug resistant bacterial infections.
Sexually transmitted disease gonorrhea is caused by the bacterium Neisseria gonorrhoeae (Ng). Most gonococcal infections are asymptomatic and can lead to pelvic disease, infertility and increased risk of HIV co-transmission.
Due to the recent emergence of multidrug resistant superbugs, Ng is now classified as an immediate public-health threat. No vaccine is available.
Led by Institute for Glycomics Director Professor Mark von Itzstein AO, the research team will build on their key discovery that Ng is sensitive to zinc-binding/carrying compounds.
“Applying our extensive experience in the fields of drug discovery and Neisseria research, we aim to develop a novel class of antibiotics to treat gonorrhea and other bacterial infections,’’ Professor von Itzstein said.
Read more at Griffith University
- Spain reports H5N1 avian influenza outbreak in Segovia
- Hong Kong: Pet store hamsters test positive for COVID-19, Temporary suspension of sales
- Argentina: Hantavirus case reported in Chubut
- China reports 4 additional H9N2 avian influenza cases in late 2021
- Slovenia: Norovirus outbreak in Ilirska Bistrica affects 123, Not linked to food
- Microbiology and the Clinical Laboratory Scientist
- Uganda reports Rift Valley Fever death in Kagadi
- Isle of Man: 1st H5N1 avian influenza cases reported in geese
- Southern China man survives Balamuthia mandrillaris infection
